Pfizer Inc. is actually a global pharmaceutical drug company that creates and manufactures goods for both equally humans and animals. Pfizer is headquartered in Nyc and employs about 121, 000 people. PRINCIPAL SERVICES AND PRODUCTS

Pfizer at the moment has 10 different sections and promotes thirty-one several major goods. The divisions and greatest major products within every single group are: Cardiovascular and Metabolic Illnesses (Lipitor, Caduet, Norvasc), Central Nervous System Disorders (Aricept, Geodon, Lyrica, Zoloft), Diabetes (Exubera), Osteoarthritis and Pain (Celebrex), Contagious and Respiratory Diseases (Diflucan, Zithromax), Urology (Detrol, Viagra), Oncology (Sutent), Opthalmology (Macugen), Endocrine Disorders (Genotropin), Other (Chantix, Zyrtec). In addition , Pfizer has 6 products which have been in the late stage of the R& D canal: UK-427, 857 for HIV treatment, Parecoxib for serious pain, Edotecarin for colorectal cancer, Torcetrapib/Lipitor for cardiovascular disease, Asenapine pertaining to bipolar disorder, and Zithromax-chloroquine for malaria. PRESENT FINANCIAL CONDITION

Pfizer's overall present financial condition is not secure, yet is trending positively intended for 2006 in comparison to the previous year. The positive trends are related to the major products the company has in its pipe. " Pfizer is ready to present six fresh medicines 5 years ago, including three (Chantix (smoking cessation), Stutent (cancer), and Exubera (diabetes)) that have billion dollar-plus potential. " A great analysis of Pfizer's financial situation will include: profits and growth, stock value, net income, cover R& M, cash flow, and EPS. Initially, Pfizer provides seen a serious decline in revenue development over the past couple of years. Pfizer noted revenues of $51, 298 million during 2005, which has been a loss of 2 . 4% over 2005. The second one fourth for 06\ showed more promising results than 2005. The income for the 2nd quarter of 2006 for the human health division had been $11 billion dollars, which is a rise of 3% compared to the second quarter of 2005 (but were still lower than earlier years. ) Second, although the second quarter revenues are elevating, Pfizer's inventory price is at present at an 8-10 year low at $25. 98. Third, Pfizer's net gain in 2005 was $8, 085 mil, which was a decrease of 29% over 2005. Fourth, Pfizer has the greatest budget for R& D spending in the industry (2004 budget was $7. several billion). 6th, Pfizer contains a strong expected cash flow within the next 40 months and expected to add up to approximately $34 billion (after capital expenditures and dividends). Lastly, Pfizer's EPS growth has been fairly stable, nevertheless has delivered a bit in the last year or so, as a result of expired uniqueness on medications. However , the most recent quarterly benefits have shown a 15. 2% increase. OBJECTIVE STATEMENT

All of us will become the world's most valued firm to sufferers, customers, colleagues, investors, business partners, plus the communities in which we job and live. COMPANY GOALS

Pfizer's business objectives for the year 2006 that consider the fact the company is extremely large, that it has a number of lucrative prescription drugs going away patent, the generic competition is elevating, and also that addresses the truth that it features light item pipelines, are as follows. The first aim and the maximum priority intended for Pfizer is to acquire companies technologies that could drive long lasting growth to get the business. Pfizer has given over $17 billion us dollars over the next 30 weeks for acquisitions. As a second objective, Pfizer is devoted to discovering and developing fresh technologies. Especially, Pfizer is interested in growth of key in-line medicines, contributions from new medicines, and R& D productivity. Pfizer's third business objective is usually to provide treatment solutions and support possibilities for both equally physicians and patients. For instance ,...


Cultural Dissimilarities Essay

Martin Luther King’s «Declaration of Self-reliance From The Battle in Vietnam, and the SNCC’s »Position Conventional paper on Vietnam